Research programme: telomerase inhibitors - XenovaAlternative Names: Telomerase inhibitors research programme - Xenova
Latest Information Update: 01 Oct 2002
At a glance
- Originator Nonindustrial source; Xenova Group
- Mechanism of Action Telomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Oct 2002 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 21 Jun 2000 New profile
- 21 Jun 2000 Preclinical development for Cancer in United Kingdom (Unknown route)